Paul Tudor Jones's AMLX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 31,334 shares of Amylyx Pharmaceuticals, Inc. (AMLX) worth $435,543, representing 0.00% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in AMLX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 33,687 shares. Largest reduction occurred in Q3 2023, reducing 32,256 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Amylyx Pharmaceuticals (AMLX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amylyx Pharmaceuticals (AMLX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +8,932 | Add 39.87% | 31,334 | $13.90 |
| Q4 2025 | +22,402 | New Buy | 22,402 | $12.08 |
| Q3 2025 | -12,073 | Sold Out | 0 | $0.00 |
| Q2 2025 | -21,355 | Reduce 63.88% | 12,073 | $6.41 |
| Q1 2025 | -259 | Reduce 0.77% | 33,428 | $3.54 |
| Q4 2024 | +33,687 | New Buy | 33,687 | $3.78 |
| Q2 2024 | -12,753 | Sold Out | 0 | $0.00 |
| Q1 2024 | -20,899 | Reduce 62.10% | 12,753 | $2.84 |
| Q4 2023 | +6,293 | Add 23.00% | 33,652 | $14.72 |
| Q3 2023 | -32,256 | Reduce 54.11% | 27,359 | $18.31 |
| Q2 2023 | +22,051 | Add 58.70% | 59,615 | $21.57 |
| Q1 2023 | +1,567 | Add 4.35% | 37,564 | $0.03 |
| Q4 2022 | +19,859 | Add 123.06% | 35,997 | $0.04 |
| Q3 2022 | +16,138 | New Buy | 16,138 | $28.13 |
Paul Tudor Jones's Amylyx Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Amylyx Pharmaceuticals, Inc. (AMLX) in Q3 2022, acquiring 16,138 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Amylyx Pharmaceuticals, Inc. (AMLX) for 14 quarters since Q3 2022.
Paul Tudor Jones's largest addition to Amylyx Pharmaceuticals, Inc. (AMLX) was in Q4 2024, adding 33,687 shares worth $127,337.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 31,334 shares of Amylyx Pharmaceuticals, Inc. (AMLX), valued at approximately $435,543.
As of the Q1 2026 filing, Amylyx Pharmaceuticals, Inc. (AMLX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Amylyx Pharmaceuticals, Inc. (AMLX) was 59,615 shares, as reported at the end of Q2 2023.